Multi-billion dollar IP dispute exposes dangers of life sciences collaborations
Seattle Genetics is demanding rights to Daiichi Sankyo’s potential blockbuster cancer treatment, which it says is an improvement on the proprietary technology included in their previous partnership
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.